Valuation: Exact Sciences Corporation

Market Cap 20.03B 103B 17.15B 16.05B 14.68B 27.63B 1,916B 27.93B 190B 73.87B 962B 75.19B 73.55B 3,184B P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 21.6B 111B 18.5B 17.3B 15.83B 29.8B 2,066B 30.12B 205B 79.67B 1,038B 81.08B 79.32B 3,433B EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
Change 5-day change 1-year change 3-year change Capi.($)
+1.12%+0.50% - - 20.03B
+2.16%+5.05%+99.92%+299.85% 4.15B
-7.79%+18.77%+208.18%+31.38% 3.76B
+1.24%+2.57%+36.48%+61.24% 3.4B
+3.45%+7.26%+274.79%+454.28% 2.51B
-3.61%+3.84%-21.05%-21.14% 2.41B
-0.88%+16.87%+27.81% - 1.48B
+4.22%+51.58%+252.65%-18.26% 1.29B
-2.40%-5.13%+16.63%+37.70% 1B
-2.72%-2.82%-36.30%+0.33% 552M
Average -0.52%+11.21%+95.46%+105.67% 2.28B
Weighted average by Cap. +0.16%+10.61%+113.05%+140.31%

Financials

2024 2025
Net sales 2.76B 14.17B 2.36B 2.21B 2.02B 3.81B 264B 3.85B 26.14B 10.18B 133B 10.36B 10.13B 439B 3.25B 16.68B 2.78B 2.6B 2.38B 4.48B 311B 4.53B 30.77B 11.98B 156B 12.19B 11.93B 516B
Net income -1.03B -5.28B -881M -824M -754M -1.42B -98.44B -1.44B -9.75B -3.8B -49.45B -3.86B -3.78B -164B -208M -1.07B -178M -167M -152M -287M -19.9B -290M -1.97B -767M -9.99B -781M -764M -33.06B
Net Debt 1.74B 8.93B 1.49B 1.39B 1.27B 2.4B 166B 2.42B 16.47B 6.41B 83.51B 6.52B 6.38B 276B 1.57B 8.07B 1.34B 1.26B 1.15B 2.17B 150B 2.19B 14.88B 5.79B 75.46B 5.9B 5.77B 250B
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. It offers a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. Its portfolio includes brands such as Cologuard and Oncotype DX, along with solutions like Cancerguard for blood-based analysis of molecular information across multiple cancers and Oncodetect for molecular residual disease and recurrence monitoring. Its flagship screening products, the Cologuard and Cologuard Plus tests, are patient-friendly, non-invasive, stool-based DNA (sDNA) screening tests that utilize a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its Cancerguard test is designed to detect multiple cancers in their earliest stages from a single blood draw. It offers predefined genetic tests for all clinically relevant genes, and whole genome (PGnome) sequencing tests.
Employees
7,150